From Wikipedia, the free encyclopedia
Glisoxepide
|
|
Names
|
Preferred IUPAC name
N-[2-(4-{[(Azepan-1-yl)carbamoyl]sulfamoyl}phenyl)ethyl]-5-methyl-1,2-oxazole-3-carboxamide
|
Identifiers
|
|
|
|
|
ChEMBL
|
|
ChemSpider
|
|
DrugBank
|
|
ECHA InfoCard
|
100.042.329
|
KEGG
|
|
|
|
UNII
|
|
|
|
InChI=1S/C20H27N5O5S/c1-15-14-18(23-30-15)19(26)21-11-10-16-6-8-17(9-7-16)31(28,29)24-20(27)22-25-12-4-2-3-5-13-25/h6-9,14H,2-5,10-13H2,1H3,(H,21,26)(H2,22,24,27) YKey: ZKUDBRCEOBOWLF-UHFFFAOYSA-N YInChI=1/C20H27N5O5S/c1-15-14-18(23-30-15)19(26)21-11-10-16-6-8-17(9-7-16)31(28,29)24-20(27)22-25-12-4-2-3-5-13-25/h6-9,14H,2-5,10-13H2,1H3,(H,21,26)(H2,22,24,27) Key: ZKUDBRCEOBOWLF-UHFFFAOYAG
|
O=C(NCCc1ccc(cc1)S(=O)(=O)NC(=O)NN2CCCCCC2)c3noc(c3)C
|
Properties
|
|
C20H27N5O5S
|
Molar mass
|
449.52388 g/mol
|
Pharmacology
|
|
A10BB11 (
WHO)
|
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Chemical compound
Glisoxepide (
INN) is an orally available
anti-diabetic drug from the group of
sulfonylureas.
[1] It belongs to second-generation sulfonylureas.
[2]
References
|
---|
|
---|
fast-acting | |
---|
short-acting | |
---|
long-acting | |
---|
ultra-long-acting | |
---|
inhalable | |
---|
|
|
|
|
---|
Calcium |
VDCCsTooltip Voltage-dependent calcium channels | |
---|
|
---|
Potassium |
VGKCsTooltip Voltage-gated potassium channels | |
---|
IRKsTooltip Inwardly rectifying potassium channel | |
---|
KCaTooltip Calcium-activated potassium channel | |
---|
K2PsTooltip Tandem pore domain potassium channel | |
---|
|
---|
Sodium |
VGSCsTooltip Voltage-gated sodium channels | |
---|
ENaCTooltip Epithelial sodium channel | |
---|
ASICsTooltip Acid-sensing ion channel | |
---|
|
---|
Chloride |
CaCCsTooltip Calcium-activated chloride channel | |
---|
CFTRTooltip Cystic fibrosis transmembrane conductance regulator | |
---|
Unsorted | |
---|
|
---|
Others |
TRPsTooltip Transient receptor potential channels | |
---|
LGICsTooltip Ligand gated ion channels | |
---|
|
---|
|